Table 1.
Clinicopathologic characteristics before and after matching.
| Characteristic | Primary cohort | PSM cohort | ||||
|---|---|---|---|---|---|---|
| Low SII | High SII | P-value | Low SII | High SII | P-value | |
| Total | 782 | 244 | 656 | 238 | ||
| Age (years) | 0.003 | 0.576 | ||||
| ≥60 | 132 (12.9%) | 22 (2.1%) | 71 (7.9%) | 22 (24.6%) | ||
| <60 | 650 (63.4%) | 222 (21.6%) | 585 (65.4%) | 216 (24.2%) | ||
| Histological type | 0.159 | 0.985 | ||||
| Invasive ductal carcinoma | 693 (67.5%) | 224 (21.8%) | 603 (67.4%) | 218 (24.4%) | ||
| Others | 89 (8.7%) | 20 (1.9%) | 53 (5.9%) | 20 (2.2%) | ||
| T stage# | 0.052 | 0.897 | ||||
| 1 | 263 (25.6%) | 71 (6.9%) | 205 (22.9%) | 71 (7.9%) | ||
| 2 | 449 (43.8%) | 141 (13.7%) | 386 (43.2%) | 141 (15.8%) | ||
| 3 | 38 (3.7%) | 18 (1.8%) | 36 (4.0%) | 16 (1.8%) | ||
| 4 | 32 (3.1%) | 14 (1.4%) | 29 (3.2%) | 10 (1.1%) | ||
| N stage# | 0.583 | 0.965 | ||||
| 0 | 414 (40.4%) | 121 (11.8%) | 331 (37.0%) | 118 (13.2%) | ||
| 1 | 195 (19.0%) | 68 (6.6%) | 168 (18.8%) | 65 (7.3%) | ||
| 2 | 101 (9.8%) | 32 (3.1%) | 91 (10.2%) | 32 (3.6%) | ||
| 3 | 72 (7.0%) | 23 (2.2%) | 66 (7.4%) | 23 (2.6%) | ||
| Clinical stage# | 0.091 | 0.925 | ||||
| I | 190 (18.5%) | 48 (4.7%) | 140 (15.7%) | 48 (5.4%) | ||
| II | 411 (40.1%) | 130 (12.7%) | 351 (39.3%) | 130 (14.5%) | ||
| III | 181 (17.6%) | 66 (6.4%) | 165 (18.5%) | 60 (6.7%) | ||
| ER | 0.838 | 0.714 | ||||
| Negative | 220 (21.4%) | 67 (6.5%) | 172 (19.2%) | 66 (7.4%) | ||
| Positive | 562 (54.8%) | 177 (17.3%) | 484 (54.1%) | 172 (19.2%) | ||
| PR | 0.319 | 0.794 | ||||
| Negative | 287 (28.0%) | 81 (7.9%) | 223 (24.9%) | 78 (8.7%) | ||
| Positive | 495 (48.2%) | 163 (15.9%) | 433 (48.4%) | 160 (17.9%) | ||
| HER2 | 0.555 | |||||
| Negative | 536 (52.2%) | 165 (16.1%) | 0.788 | 460 (51.5%) | 162 (18.1%) | |
| Positive | 246 (24.0%) | 79 (7.7%) | 196 (21.9%) | 76 (8.5%) | ||
| Ki67 | 0.934 | 0.641 | ||||
| Negative | 249 (24.3%) | 77 (7.5%) | 212 (23.7%) | 73 (8.2%) | ||
| Positive | 533 (51.9%) | 167 (16.3%) | 444 (49.7%) | 165 (18.5%) | ||
| Molecular subtype | 0.606 | 0.142 | ||||
| Luminal A | 189 (18.4%) | 55 (5.4%) | 163 (18.2%) | 54 (6.0%) | ||
| Luminal B/HER2– | 272 (26.5%) | 88 (8.6%) | 238 (26.6%) | 87 (7.8%) | ||
| Luminal B/HER2+ | 189 (18.4%) | 54 (5.3%) | 159 (17.8%) | 51 (5.7%) | ||
| HER2 enriched | 57 (5.6%) | 25 (2.4%) | 37 (4.1%) | 25 (2.8%) | ||
| Triple negative | 75 (7.3%) | 22 (2.1%) | 59 (6.6%) | 21 (2.3%) | ||
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; PSM, propensity score matching; SII, systemic immune-inflammation index.
#
According to the 7th edition of the UICC/AJCC staging system.